Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Current Deferred Revenue (2018 - 2025)

X4 Pharmaceuticals' Current Deferred Revenue history spans 2 years, with the latest figure at $464000.0 for Q4 2025.

  • For Q4 2025, Current Deferred Revenue changed N/A year-over-year to $464000.0; the TTM value through Dec 2025 reached $464000.0, changed N/A, while the annual FY2025 figure was $464000.0, N/A changed from the prior year.
  • Current Deferred Revenue reached $464000.0 in Q4 2025 per XFOR's latest filing, down from $592000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $855000.0 in Q1 2025 to a low of $464000.0 in Q4 2025.